BTCC
/
BTCC Square
/
thehindubusinessline
/
Sun Pharma (Outperform): Why This Pharma Giant Just Got a Bullish Broker Boost
Sun Pharma (Outperform): Why This Pharma Giant Just Got a Bullish Broker Boost
7
2
Sun Pharma gets the nod—analysts say 'buy' while rivals scramble.
The prescription? Growth. India's largest pharma player just scored an 'Outperform' rating, signaling confidence in its pipeline and pricing power. No surprises here—the stock's been quietly crushing it while legacy drugmakers bleed from patent cliffs.
Behind the call: Sun's specialty portfolio and US generics arm are printing cash. Meanwhile, Big Pharma CEOs are too busy lobbying against drug price reforms to notice the competition.
The kicker: In a sector where 'innovation' often means repackaging old drugs, Sun's actually expanding margins. Cynics might say that's what happens when you focus on execution instead of stock buybacks.
By:
Previous
Kaynes Technology: Why ’Hold’ Might Be the Smartest Move Right Now (2025 Outlook)
Next
Is Now the Time to Double Down on Short-Selling in Indian Markets?
